Journal of Hepatology

Article	Citations
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement	2132
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update	1558
Baveno VII – Renewing consensus in portal hypertension	931
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update	713
COVID-19: Abnormal liver function tests	653
EASL recommendations on treatment of hepatitis C: Final update of the series☆	645
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma	578
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19	446
Global burden of primary liver cancer in 2020 and predictions to 2040	446
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study	404
COVID-19 and the liver	354
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study	351
A multisociety Delphi consensus statement on new fatty liver disease nomenclature	332
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis	318
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials	293
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology	288
COVID-19: Discovery, diagnostics and drug development	288
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆	286
Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients	276
Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis	275
Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma	270
High rates of 30-day mortality in patients with cirrhosis and COVID-19	257
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma	252
Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients	251
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials	244

Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States	238
Update on NAFLD genetics: From new variants to the clinic	236
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy	223
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer	222
Systemic treatment of hepatocellular carcinoma: An EASL position paper	215
The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis	208
Global burden of liver disease: 2023 update	203
High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry	200
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores	195
Impact of COVID-19 on global HCV elimination efforts	180
Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis	176
Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis	169
Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis	166
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis	165
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients	165
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma	164
Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis	161
Epidemiology and risk-stratification of NAFLD-associated HCC	160
Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?	159
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis	157
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆	155
Single-cell genomics and spatial transcriptomics: Discovery of novel cell states and cellular interactions in liver physiology and disease biology	154
Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction	152
Sarcopenia and frailty in decompensated cirrhosis	152
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy	150
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits	150
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis	149
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis	148
The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care	145
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis	143
Animal models for liver disease – A practical approach for translational research	140
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma	136
Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping	134
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy	131
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score	129
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort	127
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry	126
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis	125
A new perspective on NAFLD: Focusing on lipid droplets	125
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases	124
Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”	122
Lytic cell death in metabolic liver disease	118
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma	118
EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis	117
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options	117
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation	116
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription	116
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy	116
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?	115
The microbiota in cirrhosis and its role in hepatic decompensation	113

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis	113
Innate immune cells in cirrhosis	113
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma	112
Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance	112
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease	112
Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial	112
Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease	112
Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma	110
IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease	110
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis	109
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease	108
Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation	108
Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension	107
Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis	107
Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view	106
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension	105
Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS	105
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease	103
MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma	102
COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma	102
Association of liver abnormalities with in-hospital mortality in patients with COVID-19	101
Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis	100
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma	100
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS)	99
Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies	98
Alternatively activated macrophages promote resolution of necrosis following acute liver injury	98
Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure	97
Combined hepatocellular-cholangiocarcinoma: An update	96
Current knowledge and management of portal vein thrombosis in cirrhosis	96
Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis	95
Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease	95
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality	95
EASL Clinical Practice Guidelines on sclerosing cholangitis	94
Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial	94
MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis	94
Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019	93
HCC surveillance after SVR in patients with F3/F4 fibrosis	92
The changing context of hepatitis D	92
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort	88
Epitranscriptomics in liver disease: Basic concepts and therapeutic potential	88
Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling	87
Impact of non-invasive biomarkers on hepatology practice: Past, present and future	87
Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis	87
Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease	86
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial	86
Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development	86
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta	84
SARS-CoV-2 infection in patients with autoimmune hepatitis	84
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial	84
Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis	83
Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure	83
Changes in frailty are associated with waitlist mortality in patients with cirrhosis	83
Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study	80
Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure	80
Portopulmonary hypertension in the current era of pulmonary hypertension management	80
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry	79
OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism	79
A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis	79
Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma	79
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA	79
Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B	78
Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis	78
Mitochondrial alterations in fatty liver diseases	78
Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma	77
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD	77
Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival	77
Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: Reversed by anti-TNF-α treatment	77
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis	75
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma	75
Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors	75
Management of bacterial and fungal infections in cirrhosis: The MDRO challenge	75
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease	75
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis	74
Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes	74
The mRNA COVID-19 vaccine – A rare trigger of autoimmune hepatitis?	74
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B	74
Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model	73
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity	73
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis	73
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?	73

Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease	73
Towards a new definition of decompensated cirrhosis	72
Another case of autoimmune hepatitis after SARS-CoV-2 vaccination – still casualty?	72
Breakthroughs in therapies for NASH and remaining challenges	72
NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly	72
Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx	72
Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity	71
Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]	71
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications	71
Hepatokines and adipokines in NASH-related hepatocellular carcinoma	71
Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality	71
Changing epidemiology, global trends and implications for outcomes of NAFLD	71
Systemic treatment of HCC in special populations	70
Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy	70
SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis	70
Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma	70
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study	70
Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease	69
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events	69
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)	69
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease	69
Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury	68
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs	68
The fecal mycobiome in non-alcoholic fatty liver disease	68
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma	67
DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer	67
Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH	67
ER stress-induced upregulation of NNMT contributes to alcohol-related fatty liver development	66
Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B	66
Autoimmune hepatitis following COVID-19 vaccination: True causality or mere association?	66
Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer	65
Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications	65
Liver injury following SARS-CoV-2 vaccination: A multicenter case series	65
Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma	65
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group	65
Cell therapy for advanced liver diseases: Repair or rebuild	64
Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication	64
Hepatic benefits of HCV cure	64
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B	64
A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma	63
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis	63
Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections	63
Genotype correlates with the natural history of severe bile salt export pump deficiency	63
Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis	63
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH	62
Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure	62
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma	62
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study	61
Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe	61
Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990–2019	61
Asian perspective on NAFLD-associated HCC	60
Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease	60
Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection	60
Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD	60
Combination immunotherapy for hepatocellular carcinoma	60
Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load	60
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes	60
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease	59
Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis	59
Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation	59
Can we use old NAFLD data under the new MASLD definition?	59
HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure	58
Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults	58
Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p	58
Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group	58
Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs	57
Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease	57
Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention	57
Bile formation and secretion: An update	57
Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites	57
NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues	57
Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality	57
Diagnosis and management of secondary causes of steatohepatitis	56
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels	56
Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies	56
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH	56
Treatment failure with DAA therapy: Importance of resistance	56
Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target	56
Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis	56
Metabolic reprogramming in cholangiocarcinoma	56
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease	55
A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA	55
48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection	55
Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis	55
Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis	55
Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis	55
Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients	55
Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis	54
Acute-on-chronic liver failure: A distinct clinical syndrome	54
Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis	54
A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation	54
Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma	54
EASL Clinical Practice Guidelines on haemochromatosis	54
Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis	53
PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma	53